Literature DB >> 4594580

Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonay embolism.

D A Tibbutt, J A Davies, J A Anderson, E W Fletcher, J Hamill, J M Holt, M L Thomas, G Lee, G A Miller, A A Sharp, G C Sutton.   

Abstract

Treatment with heparin or streptokinase was allocated randomly to 30 patients with life-threatening pulmonary embolism verified by angiography. Treatment was given for 72 hours and pulmonary angiography was repeated. There was significantly greater (P < 0.001) evidence of thrombolysis in those patients treated with streptokinase compared with those treated with heparin. The reduction of systolic and mean pulmonary arterial pressures was also significantly greater (P < 0.05 and P < 0.02 respectively) in the streptokinase group.Seven patients failed to complete 72 hours of the trial treatment: five successfully underwent pulmonary embolectomy. Six of these "failures" had initial pulmonary angiographic scores of 24 or more and systemic systolic blood pressure recordings of 100 mm Hg or less. Patients with these features should probably be considered for pulmonary embolectomy as the initial treatment.A febrile reaction commonly occurred in the streptokinase group; otherwise side effects were no more common than in the heparin group.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4594580      PMCID: PMC1633603          DOI: 10.1136/bmj.1.5904.343

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  15 in total

1.  Selection of patients with pulmonary embolism for thrombolytic therapy.

Authors:  V V Kakkar; E B Raftery
Journal:  Lancet       Date:  1970-08-01       Impact factor: 79.321

2.  Massive pulmonary embolism.

Authors:  E Turnier; J D Hill; W J Kerth; F Gerbode
Journal:  Am J Surg       Date:  1973-05       Impact factor: 2.565

3.  The diagnosis and management of massive pulmonary embolism.

Authors:  G A Miller
Journal:  Br J Surg       Date:  1972-10       Impact factor: 6.939

4.  Resolution rate of acute pulmonary embolism in man.

Authors:  J E Dalen; J S Banas; H L Brooks; G L Evans; J A Paraskos; L Dexter
Journal:  N Engl J Med       Date:  1969-05-29       Impact factor: 91.245

5.  Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism.

Authors:  G A Miller; G C Sutton; I H Kerr; R V Gibson; M Honey
Journal:  Br Med J       Date:  1971-06-19

6.  Observations on the fate of large pulmonary emboli.

Authors:  A Chait; D Summers; N Krasnow; B M Wechsler
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1967-06

7.  Rapid resolution of pulmonary thromboemboli in man. An angiographic study.

Authors:  H L Fred; M A Axelrad; J M Lewis; J K Alexander
Journal:  JAMA       Date:  1966-06-27       Impact factor: 56.272

8.  Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism.

Authors:  D P Thomas; V Gurewich; T P Ashford
Journal:  N Engl J Med       Date:  1966-04-28       Impact factor: 91.245

9.  Streptokinase therapy in acute major pulmonary embolism: effectiveness and problems.

Authors:  J Hirsh; G S Hale; I G McDonald; R A McCarthy; A Pitt
Journal:  Br Med J       Date:  1968-12-21

10.  Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism.

Authors:  J Hirsh; I G McDonald; G A Hale; E F O'Sullivan; V M Jelinek
Journal:  Can Med Assoc J       Date:  1971-03-20       Impact factor: 8.262

View more
  36 in total

Review 1.  The pulmonary physician and critical care. 5. Management of pulmonary embolism.

Authors:  H H Gray; S Firoozan
Journal:  Thorax       Date:  1992-10       Impact factor: 9.139

Review 2.  When should we thrombolyse patients with pulmonary embolism? A systematic review of the literature.

Authors:  T Harris; S Meek
Journal:  Emerg Med J       Date:  2005-11       Impact factor: 2.740

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Suspected acute pulmonary embolism: a practical approach. British Thoracic Society, Standards of Care Committee.

Authors: 
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

Review 5.  The role of thrombolytic therapy in pulmonary embolism.

Authors:  Tzu-Fei Wang; Alessandro Squizzato; Francesco Dentali; Walter Ageno
Journal:  Blood       Date:  2015-01-28       Impact factor: 22.113

Review 6.  Fibrinolysis for Acute Care of Pulmonary Embolism in the Intermediate Risk Patient.

Authors:  Guy Meyer; Benjamin Planquette; Olivier Sanchez
Journal:  Curr Atheroscler Rep       Date:  2015-12       Impact factor: 5.113

Review 7.  Can thrombus age guide thrombolytic therapy?

Authors:  Christopher Czaplicki; Hassan Albadawi; Sasan Partovi; Ripal T Gandhi; Keith Quencer; Amy R Deipolyi; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

8.  Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.

Authors:  Ariel Izcovich; Juan M Criniti; Federico Popoff; Liming Lu; Jiaming Wu; Walter Ageno; Daniel M Witt; Michael R Jaff; Sam Schulman; Veena Manja; Peter Verhamme; Gabriel Rada; Yuqing Zhang; Robby Nieuwlaat; Wojtek Wiercioch; Holger J Schünemann; Ignacio Neumann
Journal:  Blood Adv       Date:  2020-04-14

Review 9.  Antithrombotic drugs: part II.

Authors:  A S Gallus; J Hirsh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Pulmonary embolectomy for acute massive pulmonary embolism: an analysis of 71 cases.

Authors:  H H Gray; J M Morgan; M Paneth; G A Miller
Journal:  Br Heart J       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.